Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 24Leukemia, Myeloid, Acute 14Leukemia, Myelomonocytic, Chronic 7Leukemia 6Polycythemia Vera 3Anemia 3Primary Myelofibrosis 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Recurrence 1Preleukemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hematologic Diseases 1GATA2 Deficiency 1

Interventions

Azacitidine 3Specimen Handling 2Nivolumab 2venetoclax 1regorafenib 1midostaurin 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × Lenalidomide × Myeloid × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡